Cite
HARVARD Citation
Wang, L. et al. (n.d.). 131P First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC. Immuno-oncology technology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wang, L. et al. (n.d.). 131P First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC. Immuno-oncology technology. p. . [Online].